Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rapid Micro Biosystems (RPID) Long-Term Debt Repayments (2021)

Rapid Micro Biosystems recorded quarterly Long-Term Debt Repayments of -$26.1 million in Q4 2021.

Rapid Micro Biosystems' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at -$26.1 million for Q4 2021.

  • In Q4 2021, Long-Term Debt Repayments changed N/A year-over-year to -$26.1 million; the TTM figure through Dec 2022 stood at -$26.1 million (changed N/A YoY), while the FY2021 annual figure was $12000.0, down 99.93% from the prior year.
  • Long-Term Debt Repayments came in at -$26.1 million for Q4 2021 at Rapid Micro Biosystems.
  • In the past five years, Long-Term Debt Repayments ranged from a high of -$26.1 million in Q4 2021 to a low of -$26.1 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Rapid Micro Biosystems 89.50 Mn 66.56 Mn 371,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 -26.15 Mn
Dec 31, 2021 -26.15 Mn